Navigation Links
Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
Date:10/3/2007

A Fully Automated, Portable Solution for In-Clinic and Out-Reach Influenza

Testing

PORTON DOWN, England, October 3 /PRNewswire/ -- Enigma Diagnostics, the life sciences company developing rapid molecular diagnostics and detection systems, announces a EUR3 million award from the European Commission Framework 7 programme to the RANGER consortium. The award will fund the development and validation of a fully automated, low cost system for the rapid diagnosis of influenza infections and subtypes.

The RANGER consortium, which is coordinated by Enigma Diagnostics, comprises leading technology companies including Applied Biosystems, Sagentia, Tico Europe, Bruhn Newtech Group, Bioplastics BV and PERA who will contribute to the development of the instrument and assays. The consortium also includes the Health Protection Agency, the UK's national reference laboratory for influenza diagnostics, and the Queen Sirikit National Institute of Child Health who will evaluate and validate the system.

The system will be based on Enigma's proprietary and fully-automated instrumentation technology, which integrates sample preparation with real-time polymerase chain reaction (PCR) to detect viral RNA in a full range of clinical samples. The simple-to-use, portable system will provide rapid results direct to medical staff in a near-patient or out-reach environment in both the developed and developing world.

By providing laboratory standard, high specificity and sensitivity PCR results in a decentralised setting, the system will advance the diagnosis of early stage viral infections and the surveillance of disease outbreaks.

Enigma is also separately developing real-time PCR-based diagnostics systems targeting chlamydia, gonorrhoea and other sexually transmitted infections.

John McKinley, Chairman of Enigma Diagnostics, said: "The award of this grant and the strength of our consortium partners is a great endorsement of Enigma's technology. It is also a strategically important milestone for the company as it demonstrates the utility of our real time PCR in what is an extremely challenging area of diagnosis. We are confident we will be able to deliver a system that rapidly and simply delivers laboratory quality results at the point of care."


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Diagnostics Corporation
2. Roche Diagnostics Corporation
3. A prognosis for GE and Abbott Diagnostics
4. The world of in-vitro diagnostics is another Midwest success story
5. The world of in vitro diagnostics is another Midwest success story
6. Midwest holds strong position in worldwide diagnostics business
7. BioDiagnostics is first seed-testing lab to gain new accreditation
8. Speaker announces business members of IT Task Force
9. Doyle announces technology tax credits for Berbee
10. Doyle announces new energy, global warming policies
11. Doyle announces $80M renewable energy strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
Breaking Biology Technology:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
Breaking Biology News(10 mins):